Georgia Broadens Medical Marijuana Access, Bringing Relief to Thousands of New Patients

Georgia’s expanded medical cannabis law took effect on Wednesday, July 1, broadening access for more residents. Currently, this Southern State has roughly 35,000 registered medical cannabis patients.

Under the “Putting Georgia’s Patients First Act,” or Senate Bill 220, which was signed into law by Governor Brian Kemp on May 12, 2026, patients with HIV, lupus, or irritable bowel syndrome (IBS) are now eligible, as these conditions have been added to the list of qualifying conditions, reported FOX 5 Atlanta.

Tim Morey with Trulieve medical cannabis dispensary in Marietta said they are “ready to serve more people with the expanded recommendations and qualifications.”  He expects the patient count to grow significantly by the year-end.

The new law removed the previous 5% THC cap on medical cannabis products, allowing patients to purchase up to 1,200 mg of THC per item and up to 12,000 mg of THC per transaction.

Moreover, patients can now legally use vaporized medical cannabis products, a faster-acting option that usually takes effect in 10–15 minutes.

“If you’re in pain, or you’re in a crisis, you want that onset as fast as you can get it,” Morey emphasized.

Georgia’s latest policy change also allows over a hundred independent pharmacies statewide to dispense medical cannabis.

While the law has effectively set up a natural growth for the industry, there are still only six production licenses, 15 retail licenses, and one independent testing lab allowed in Georgia, as reported by Marijuana Business Daily.

That said, Trulieve Cannabis Corp . (NYSE: TRLV) already boasts an established presence in Georgia.

At the Marietta location, the first sale, purchased by retired army veteran Desi Cleveland, included the Roll One Clutch All in One vape and Modern Flower whole flower, both available for the first time in Georgia, Trulieve said in a press release.

Botanical Sciences is, at the time, its strongest direct competitor, holding one of only two Class 1 licenses that allow substantial cultivation capacity, operating several dispensaries, and backed by pharmacy distribution.

TRLV Price Action

Trulieve’s shares traded 0.59% lower at $9.48 per share at the time of writing on Thursday.